Patients with cancers that harbor an IDH1 mutation should consider discussing ivosidenib treatment with their oncologist. Genetic testing is required to confirm the presence of the IDH1 mutation. If the mutation is present, ivosidenib may be a viable treatment option, particularly for those who have not responded to other therapies or who are not candidates for intensive chemotherapy.
